To the best of our knowledge, this is the first demonstration that increased expression of PD-L2 may serve as a marker for decreased progression-free survival, providing justification for further investigation into the PD1/PD-L2 axis and PD-L2 based immunotherapy as a strategy to treat ovarian cancer. Here, PDCD1LG2 is linked to ovarian carcinoma.